Spotlights

Home/Spotlights

Spotlight: Biotech Companies in the “Big 3” Regions Rake in the Cash

  BioWeekSF will soon be here again — January 5-10, 2019 — the week of the J.P. Morgan Healthcare Conference and 20 other events and forums. In preparation, the week’s premium online guide, BioWeekSF.com, is showcasing a series of reports and other resources focusing on financing and dealmaking. This feature is from DealForma, the biopharma database providing you [...]

November 13th, 2018|

Spotlight: What Small and Emerging Companies Need When Entering Into Dealmaking Discussions

BioWeekSF will soon be here again -- January 6-11, 2019 -- the week of the J.P. Morgan Healthcare Conference and 20 other events and forums. In preparation,  the week's premium online guide, BioWeekSF.com, is sponsoring a series of viewpoints and more from leaders and professionals involved in life sciences/healthcare dealmaking. As Chair of Foley Hoag's Licensing & [...]

October 14th, 2018|

Spotlight: EPPICon’s 18th Annual Meeting

EPPICon's 18th Annual Meeting is just around the corner featuring sessions on digital health, data driven drug discovery, and personalized genomics using bioinformatics. EPPIC Global’s mission is to advance healthcare by providing entrepreneurship, mentoring and networking opportunities. Since 1998, EPPIC Global has promoted interactions at the intersection of tech and healthcare to surface innovative ideas [...]

September 10th, 2018|

Spotlight: 3rd Annual Viral Clearance and Viral Safety Summit

Charles River is excited to announce its 3rd Annual Viral Clearance and Viral Safety Summit on October 9-10, 2018 in San Francisco, CA. We have lined up speakers from the Paul Ehrlich Institute, Lysogene, Amgen, Boehringer Ingelheim and CSL Behring among other companies to bring you a comprehensive look at current industry and regulatory practices [...]

August 13th, 2018|

Spotlight: The Elizabeth Holmes and Theranos Saga

Since 2014, Big3Bio has shared the rise-and-fall coverage of Elizabeth Holmes and Theranos. With the most recent development of Holmes being indicted, we'll keep this post updated throughout the rest of 2018. UPDATED COVERAGE 9/5/18 Theranos to Dissolve -  The Wall Street Journal 8/23/18 Bad Blood Author Carreyrou On Elizabeth Holmes And Theranos - CNBC [...]

June 18th, 2018|

Spotlight: Translational Biomarkers Event on May 14th

With so many patients relying on novel therapeutics for neurological disorders, the stakes are high when therapies reach the clinic. The best way to improve your chance for success is to design rigorous preclinical studies that include reproducible endpoints and robust biomarkers that predict clinical efficacy. Charles River hopes you join us as we further [...]

April 25th, 2018|

Spotlight: Interrogating the Immune System for Diagnosing Infection

Startup Inflammatix, founded in 2016 in Burlingame, California, takes a different approach to diagnosing infections. Rather than seeking the pathogen causing the infection, it uses a data-driven approach to evaluate the body’s immune system response to provide a diagnosis in as little as an hour. Big3Bio editor Marie Daghlian spoke with Dr. Timothy Sweeney, co-founder [...]

March 9th, 2018|

Charles River’s 2nd Annual Viral Safety and Viral Clearance Summit

Charles River’s 2nd Annual Viral Safety and Viral Clearance Summit will be held October 10 – 11, 2017 at the San Mateo Marriott in San Mateo, CA. The 2-day summit, located in the Bay Area, unites industry professionals in an interactive setting to share updates and discuss trends in the realm of viral safety and [...]

August 3rd, 2017|

Charles River 23rd Annual Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development Symposium

The Charles River 23rd Annual Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development symposium will be held September 11-13, 2017 at Cape Rey Resort, Carlsbad, CA. This three-day symposium with five sessions has a jam-packed agenda with case study presentations from industry leaders from Bluebird, Janssen, Pfizer and Amgen in the nonclinical development of biotherapeutics. Don’t miss out on [...]

July 18th, 2017|
X